{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:50:51Z","timestamp":1792605051524,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02028-w","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:09:07Z","timestamp":1744960147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-5039","authenticated-orcid":false,"given":"Lanfranco","family":"Pellesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3662-5582","authenticated-orcid":false,"given":"Thien Phu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-3823","authenticated-orcid":false,"given":"Martin Thomsen","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8097-8708","authenticated-orcid":false,"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-5679","authenticated-orcid":false,"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"2","key":"2028_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34(2):114\u2013125. https:\/\/doi.org\/10.1177\/0333102413500727","journal-title":"Cephalalgia"},{"issue":"2","key":"2028_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an oral calcitonin Gene-Related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"issue":"10200","key":"2028_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of Rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X","journal-title":"Lancet"},{"issue":"10268","key":"2028_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral Rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7","journal-title":"Lancet"},{"issue":"7","key":"2028_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Rimegepant: first approval. Drugs 80(7):741\u2013746. https:\/\/doi.org\/10.1007\/s40265-020-01301-3","journal-title":"Drugs"},{"key":"2028_CR6","unstructured":"European Medicines Agency. VYDURA 75\u00a0mg oral lyophilisate: EU summary of product characteristics (2022) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura. Accessed 2 Dec 2024"},{"issue":"3","key":"2028_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The arrival of Anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 19(3):922\u2013930. https:\/\/doi.org\/10.1007\/s13311-022-01230-x","journal-title":"Neurotherapeutics"},{"key":"2028_CR8","doi-asserted-by":"publisher","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM et al (2024) Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ. 2024;386:e080107. https:\/\/doi.org\/10.1136\/bmj-2024-080107","DOI":"10.1136\/bmj-2024-080107"},{"key":"2028_CR9","unstructured":"Bendtsen L, Aegidius K, Amin FA, Carlsen LN, Hansen JM, Jensen RH et al (2020) Referenceprogram\u2013 Diagnostik og behandling af hovedpinesygdomme og ansigtssmerter. Dansk Hovedpine Selskab, 3. edition. Eget forlag 2020;1\u201383. http:\/\/dhos.dk\/wp-content\/uploads\/2020\/05\/Referenceprogram2020.pdf"},{"issue":"7 Suppl","key":"2028_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"H Wallach Kildemoes","year":"2011","unstructured":"Wallach Kildemoes H, Toft S\u00f8rensen H, Hallas J (2011) The Danish National prescription registry. Scand J Public Health 39(7 Suppl):38\u201341. https:\/\/doi.org\/10.1177\/1403494810394717","journal-title":"Scand J Public Health"},{"key":"2028_CR11","unstructured":"World Health Organization (2020) WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC Classification and DDD Assignment 2021. https:\/\/edisciplinas.usp.br\/pluginfile.php\/6802122\/mod_resource\/content\/1\/24rd Guidelines ATC-DDD.pdf"},{"issue":"1","key":"2028_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/EDE.0000000000001666","volume":"35","author":"H Harbi","year":"2024","unstructured":"Harbi H, Potteg\u00e5rd A (2024) Validation of the indication for use (INDO) variable in the Danish National prescription registry. Epidemiology 35(1):1\u20136. https:\/\/doi.org\/10.1097\/EDE.0000000000001666","journal-title":"Epidemiology"},{"key":"2028_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HAT (2015) The Danish National patient registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449\u2013490. https:\/\/doi.org\/10.2147\/CLEP.S91125","journal-title":"Clin Epidemiol"},{"issue":"7 Suppl","key":"2028_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen CB (2011) The Danish civil registration system. Scand J Public Health 39(7 Suppl):22\u201325. https:\/\/doi.org\/10.1177\/1403494810387965","journal-title":"Scand J Public Health"},{"key":"2028_CR15","unstructured":"The WHO Collaborating Centre for Drug Statistics Methodology (2024) https:\/\/atcddd.fhi.no\/atc_ddd_index\/?code=N02CD06. Accessed 20 Mar 2025"},{"issue":"8","key":"2028_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/pds.4582","volume":"27","author":"L Rasmussen","year":"2018","unstructured":"Rasmussen L, Pratt N, Hansen MR, Hallas J, Potteg\u00e5rd A (2018) Using the proportion of patients covered and the Kaplan-Meier survival analysis to describe treatment persistence. Pharmacoepidemiol Drug Saf 27(8):867\u2013871. https:\/\/doi.org\/10.1002\/pds.4582","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"2028_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501\u2013514. https:\/\/doi.org\/10.1038\/s41582-021-00509-5","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2028_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"K Johnston","year":"2022","unstructured":"Johnston K, Harris L, Powell L, Popoff E, Coric V, L\u2019Italien G et al (2022) Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J Headache Pain 23(1):10. https:\/\/doi.org\/10.1186\/s10194-021-01378-5","journal-title":"J Headache Pain"},{"key":"2028_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/JPR.S456006","volume":"17","author":"T Fullerton","year":"2024","unstructured":"Fullerton T, Pixton G (2024) Long-Term use of Rimegepant 75\u00a0mg for the acute treatment of migraine is associated with a reduction in the utilization of select analgesics and antiemetics. J Pain Res 17:1751\u20131760. https:\/\/doi.org\/10.2147\/JPR.S456006","journal-title":"J Pain Res"},{"key":"2028_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/DHPS.S304373","volume":"13","author":"F Lo Castro","year":"2021","unstructured":"Lo Castro F, Guerzoni S, Pellesi L (2021) Safety and risk of medication overuse headache in Lasmiditan and Second-Generation Gepants: A rapid review. Drug Healthc Patient Saf 13:233\u2013240. https:\/\/doi.org\/10.2147\/DHPS.S304373","journal-title":"Drug Healthc Patient Saf"},{"issue":"6","key":"2028_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138.z","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478\u2013488. https:\/\/doi.org\/10.1177\/0333102414547138.z","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02028-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02028-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02028-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:09:13Z","timestamp":1744960153000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02028-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02028-w","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.P. was formerly employed by Lundbeck. T.P.D. has received personal fees from Teva that are unrelated to this manuscript. J.H. and A.P. reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, Pfizer and LEO Pharma (all regulator-mandated Phase IV studies), and an unrestricted research grant from Novo Nordisk, all with funds paid to the institution where they were employed (no personal fees) and with no relation to the work reported in this paper. M.T.E. reports no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}